Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...

No improvement in overall survival (OS) was observed with palbociclib (Verzenio) plus endocrine therapy versus capecitabine ...

This was the stock's third consecutive day of gains.

At the State of Black Health second annual summit hosted by BlackDoctor.org in partnership with USA TODAY, corporate leaders ...

A high omega-3, low omega-6 diet with fish oil led to a significant reduction in a biomarker for prostate cancer progression ...

Neoadjuvant chemoimmunotherapy for muscle-invasive bladder cancer (MIBC) followed by risk-adapted therapy led to high rates ...

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...

Bernstein raised the firm’s price target on Gilead (GILD) to $120 from $105 and keeps an Outperform rating on the shares. The firm notes Gilead ...

We recently published a list of 10 Stocks That Analysts Think Will Go Up. In this article, we are going to take a look at ...

Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

Manufacturers of medicines, including Pfizer and Eli Lilly, have spent a combined $450,000 lobbying against price caps on ...

The board of Gilead Sciences, Inc. (NASDAQ:GILD) has announced that the dividend on 28th of March will be increased to $0.79, ...